Table 1.

List of Major Oxygen Trials

Trial	Dates	Enrolled	Exclusion	% not meeting inclusion criteria	Geography	Birth weight (mean or range)	Intervention	Outcome	Mortality
STOP-ROP	1994–1999	30–48 weeks GA with prethreshold ROP in one eye and median SaO2 <94%	Median SaO2>94% or congenital abnormality	34%	United States	726 grams	Infants randomized to SaO2 ranges of 89–94% or 96–99%	No significant difference in threshold ROP. In subgroup, threshold ROP < infants without Plus disease in 96–99% SaO2 group	Not assessed formally 7 infants in lower oxygen tension group vs. 9 infants in the higher tension group died)
Support	2005–2009	24–27 weeks GA 6 days at birth who underwent full resuscitation	Infants with major congenital abnormalities	6.6%	United States	825–836 grams	Randomized to early CPAP or early surfactant Randomized to SaO2 of 85–89% or 91–95%	Decreased ROP in 85–89% SaO2 group	Increased mortality in 85–89% SaO2 group
BOOST II	2006–2011	<28 weeks GA	Unlikely to survive Major congenital abnormality Unavailable for follow up	9%	Australia, UK, New Zealand	826–837 grams	Randomized to SaO2 of 85–89% or 91–95%	Decreased ROP in 85–89% SaO2 group	Increased mortality when targeting SaO2 <90%
COT	2006–2012	>23 weeks to 27 weeks and 6 days GA	Not viable Persistent pulmonary hypertension Dysmorphic features or congenital malformations Cyanotic heart disease Unavailable for follow up	16%	Canada, United States, Argentina Finland, Germany Israel	827–845 grams	Randomized to SaO2 of 85–89% or 91–95%	No significant difference between SaO2 targets on ROP at 18 months	No significant difference between SaO2 targets on death or disability at 18 months

GA-gestational age; SaO_{2 –} oxygen saturation; STOP-ROP - Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity; BOOST – Benefits of Oxygen Saturation Targeting; SUPPORT - Surfactant, Positive Airway Pressure, Pulse Oximetry Randomized Trial; COT – Canadian Oxygen Trial